Literature DB >> 35763977

Charting the proteome landscape in major psychiatric disorders: From biomarkers to biological pathways towards drug discovery.

Brisa S Fernandes1, Yulin Dai1, Peilin Jia1, Zhongming Zhao2.   

Abstract

Schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD) are major mental disorders that affect a significant proportion of the global population. Advancing our knowledge of the pathophysiology of these disorders and identifying biomarkers are urgent needs for developing objective diagnostic tests and new therapeutics. In this study, we performed a systematic review and then extracted, curated, and analyzed proteomics data from published studies, aiming to assess the proteome in peripheral blood of individuals with SZ, BD, or MDD. Then, we performed pathway and network analyses to illuminate the biological themes concatenated by the differentially expressed proteins by systematically interrogating the literature to uncover biological pathways with more robust biological meaning. We identified 486 differentially expressed proteins from 51 studies across the three disorders with 9,423 participants. The great majority of pathways were common to SZ, BD, and MDD. They were related to the immune system, including signaling by interleukins, Toll-like receptor signaling pathway, and complement cascade, and to signal transduction, notably MAPK1/MAPK3 signaling, PI3K-Akt Signaling Pathway, Focal Adhesion-PI3K-Akt-mTOR-signaling, rhodopsin-like receptors, GPCR signaling, and the JAK-STAT signaling pathway. Other shared pathways included advanced glycosylation end-product receptor signaling, Regulation of Insulin-like Growth Factor, cholesterol metabolism, and IL-17 signaling pathway. Pathways shared between SZ and BD were integrin cell-surface interactions, GRB2:SOS provides linkage to MAPK signaling for integrins, and syndecan interactions. Shared between BD and MDD were the NRF2 pathway and signaling by EGFR pathways. Our findings advance our understanding of the protein variations and associations with these disorders, which are useful for accelerating biomarker development and drug discovery.
Copyright © 2022 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Biological pathways; Bipolar disorder; Drug development; Major depressive disorder; Proteomics; Schizophrenia

Mesh:

Substances:

Year:  2022        PMID: 35763977      PMCID: PMC9378550          DOI: 10.1016/j.euroneuro.2022.06.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   5.415


  52 in total

1.  Characterization of genome-wide association study data reveals spatiotemporal heterogeneity of mental disorders.

Authors:  Yulin Dai; Timothy D O'Brien; Guangsheng Pei; Zhongming Zhao; Peilin Jia
Journal:  BMC Med Genomics       Date:  2020-12-28       Impact factor: 3.063

2.  Clinical development success rates for investigational drugs.

Authors:  Michael Hay; David W Thomas; John L Craighead; Celia Economides; Jesse Rosenthal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

Review 3.  C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis.

Authors:  Brisa S Fernandes; Johann Steiner; Marc L Molendijk; Seetal Dodd; Patricia Nardin; Carlos-Alberto Gonçalves; Felice Jacka; Cristiano A Köhler; Chandan Karmakar; André F Carvalho; Michael Berk
Journal:  Lancet Psychiatry       Date:  2016-11-10       Impact factor: 27.083

Review 4.  Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression.

Authors:  Charlotte D'Mello; Mark G Swain
Journal:  Curr Top Behav Neurosci       Date:  2017

5.  Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis.

Authors:  Brisa Simões Fernandes; Clarissa Severino Gama; Marcia Kauer-Sant'Anna; Maria Ines Lobato; Paulo Belmonte-de-Abreu; Flavio Kapczinski
Journal:  J Psychiatr Res       Date:  2009-06-06       Impact factor: 4.791

6.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

7.  Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies.

Authors:  Brisa S Fernandes; Marc L Molendijk; Cristiano A Köhler; Jair C Soares; Cláudio Manuel G S Leite; Rodrigo Machado-Vieira; Thamara L Ribeiro; Jéssica C Silva; Paulo M G Sales; João Quevedo; Viola Oertel-Knöchel; Eduard Vieta; Ana González-Pinto; Michael Berk; André F Carvalho
Journal:  BMC Med       Date:  2015-11-30       Impact factor: 8.775

8.  Unexpected role of interferon-γ in regulating neuronal connectivity and social behaviour.

Authors:  Anthony J Filiano; Yang Xu; Nicholas J Tustison; Rachel L Marsh; Wendy Baker; Igor Smirnov; Christopher C Overall; Sachin P Gadani; Stephen D Turner; Zhiping Weng; Sayeda Najamussahar Peerzade; Hao Chen; Kevin S Lee; Michael M Scott; Mark P Beenhakker; Vladimir Litvak; Jonathan Kipnis
Journal:  Nature       Date:  2016-07-13       Impact factor: 49.962

Review 9.  Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders.

Authors:  André F Carvalho; Marco Solmi; Marcos Sanches; Myrela O Machado; Brendon Stubbs; Olesya Ajnakina; Chelsea Sherman; Yue Ran Sun; Celina S Liu; Andre R Brunoni; Giorgio Pigato; Brisa S Fernandes; Beatrice Bortolato; Muhammad I Husain; Elena Dragioti; Joseph Firth; Theodore D Cosco; Michael Maes; Michael Berk; Krista L Lanctôt; Eduard Vieta; Diego A Pizzagalli; Lee Smith; Paolo Fusar-Poli; Paul A Kurdyak; Michele Fornaro; Jürgen Rehm; Nathan Herrmann
Journal:  Transl Psychiatry       Date:  2020-05-18       Impact factor: 6.222

10.  Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients.

Authors:  E Schwarz; P C Guest; J Steiner; B Bogerts; S Bahn
Journal:  Transl Psychiatry       Date:  2012-02-21       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.